Select Transactions
|
| Acquisition of generics business of |
|
|
$1.05 billion
June 2017
|
|
| Sale of Intrathecal business to |
|
|
$203 million
March 2017
|
|
| Microbiome partnership with |
|
|
$2.6 billion
($50 million upfront) January 2017
|
|
| Royalty-backed acquisition financing for undisclosed spec pharma |
|
|
$100 million
February 2016
|
Torreya is a leading strategic M&A advisor to global life sciences companies. MORE
Torreya is one of the most active financial advisors on pharmaceutical-product asset sales. MORE
Torreya’s Capital Markets team arranges debt financings, royalty monetizations, IPOs, and private equity recapitalizations. MORE
Torreya is a leading advisor on pre-commercial and commercial-stage licensing deals. MORE
As we mark our 10-year anniversary, Torreya emerges as a leading advisor in global life sciences transactions.
- #1 by transaction volume—M&A and Licensing1
- Advised on over 20 assignments in 2017 through September 30
- Strong Capital Markets practice with over $1.5 billion raised
1 Capital IQ and Torreya calculations: September 2017